Role of Dynamic MRI and Clinical Assessment in Predicting Histologic Response to Neoadjuvant Chemotherapy in Bone Sarcomas

2014 ◽  
Vol 37 (4) ◽  
pp. 384-390 ◽  
Author(s):  
Priyadarshi Amit ◽  
Dilip K. Patro ◽  
Debdatta Basu ◽  
Sundar Elangovan ◽  
Vadasoundaram Parathasarathy
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Clinical Assessment ◽  
Dynamic Mri ◽  
Histologic Response ◽  
Bone Sarcomas ◽  
Response To Neoadjuvant Chemotherapy

Disparate histologic responses in simultaneously resected primary and metastatic osteosarcoma following intravenous neoadjuvant chemotherapy.

1987 ◽  
Vol 5 (8) ◽  
pp. 1185-1190 ◽  
Author(s):  
J Nachman ◽  
M A Simon ◽  
L Dean ◽  
D Shermeta ◽  
P Dawson ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Primary Tumor ◽  
Metastatic Tumor ◽  
Cell Heterogeneity ◽  
Newly Diagnosed ◽  
Histologic Response ◽  
Postoperative Therapy ◽  
Metastatic Osteosarcoma ◽  
Tumor Cell Heterogeneity ◽  
Response To Neoadjuvant Chemotherapy

Seven patients with newly diagnosed metastatic osteosarcoma underwent simultaneous resection of the primary tumor and metastases following intravenous (IV) neoadjuvant chemotherapy. Histologic response was assessed in all tumor specimens. Disparate responses were noted between primary tumor and metastases and, in some cases, between two or more metastatic tumor deposits. The diverse histologic response to neoadjuvant chemotherapy suggests tumor cell heterogeneity. Changing postoperative therapy on the basis of the histologic response induced in the primary tumor may not be appropriate.

scholarly journals Clinical Features, Treatment, and Outcome in 102 Adult and Pediatric Patients with Localized High-Grade Synovial Sarcoma

Sarcoma ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
H. Al-Hussaini ◽  
D. Hogg ◽  
M. E. Blackstein ◽  
B. O'Sullivan ◽  
C. N. Catton ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Synovial Sarcoma ◽  
Surgical Resection ◽  
Pediatric Patients ◽  
Response Rate ◽  
High Grade ◽  
En Bloc ◽  
Positive Surgical Margins ◽  
Response To Neoadjuvant Chemotherapy

Background. There remains controversy on the routine use of chemotherapy in localized SS.Methods. The records of 87 adult (AP) and 15 pediatric (PP) patients with localized SS diagnosed between 1986 and 2007 at 2 centres in Toronto were reviewed.Results. Median age for AP and PP was 37.6 (range 15–76) and 14 (range 0.4–18) years, respectively. 65 (64%) patients had large tumours (>5 cm). All patients underwent en bloc surgical resection resulting in 94 (92.2%) negative and 8 (7.8%) microscopically positive surgical margins. 72 (82.8%) AP and 8 (53%) PP received radiotherapy. Chemotherapy was administered to 12 (13.8%) AP and 13 (87%) PP. 10 AP and 5 PP were evaluable for response to neoadjuvant chemotherapy, with response rate of10%and40%, respectively. 5-year EFS and OS was69.3±4.8%and80.3±4.3%, respectively, and was similar for AP and PP, In patients with tumors >5 cm, in whom chemotherapy might be considered most appropriate, relapse occurred in 9/19 (47%) with chemotherapy, compared to 17/46 (37%) In those without.Conclusions. Patients with localized SS have a good chance of cure with surgery and RT. Evidence for a well-defined role of chemotherapy to improve survival In localized SS remains elusive.

[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors

2005 ◽  
Vol 23 (34) ◽  
pp. 8828-8834 ◽  
Author(s):  
Douglas S. Hawkins ◽  
Scott M. Schuetze ◽  
James E. Butrynski ◽  
Joseph G. Rajendran ◽  
Cheryl B. Vernon ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Neoadjuvant Chemotherapy ◽  
Ewing Sarcoma ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Disease Stage ◽  
Significant Prognostic Factor ◽  
Histologic Response ◽  
Positron Emission ◽  
Response To Neoadjuvant Chemotherapy

Purpose Response to neoadjuvant chemotherapy is a significant prognostic factor for the Ewing sarcoma family of tumors (ESFTs). [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) is a noninvasive imaging modality that accurately predicts histopathologic response in several malignancies. To determine the prognostic value of FDG PET response for progression-free survival (PFS) in ESFTs, we reviewed the University of Washington Medical Center experience. Patients and Methods Thirty-six patients with ESFTs were evaluated by FDG PET. All patients received neoadjuvant and adjuvant chemotherapy. FDG PET standard uptake values before (SUV1) and after (SUV2) chemotherapy were analyzed and correlated with chemotherapy response, as assessed by histopathology in surgically excised tumors. Thirty-four patients had both SUV1 and SUV2. Results The mean SUV1, SUV2, and ratio of SUV2 to SUV1 (SUV2:1) were 7.9 (range, 2.3 to 32.8), 2.1 (range, 0 to 4.3), and 0.36 (range, 0.00 to 1.00), respectively. Good FDG PET response was defined as SUV2 less than 2.5 or SUV2:1 ≤ 0.5. FDG PET response by SUV2 or SUV2:1 was concordant with histologic response in 68% and 69% of patients, respectively. SUV2 was associated with outcome (4-year PFS 72% for SUV2 < 2.5 v 27% for SUV2 ≥ 2.5, P = .01 for all patients; 80% for SUV2 < 2.5 v 33% for SUV2 ≥ 2.5, P = .036 for localized at diagnosis patients). SUV2:1 ≤ 0.5 was not predictive of PFS. Conclusion FDG PET imaging of ESFTs correlates with histologic response to neoadjuvant chemotherapy. SUV2 less than 2.5 is predictive of PFS independent of initial disease stage.

Sign in / Sign up

Export Citation Format

Share Document